Lilly Gets Second EUA, For Baricitinib In COVID-19 Patients

Weeks after FDA authorized emergency use of its antibody bamlanivimab, Lilly’s RA drug Olumiant can be used to shorten recovery time for hospitalized COVID-19 patients in the US. Authorizations are being pursued elsewhere as well.

Coronavirus globe
Lilly's second EUA for a COVID-19 therapy covers Olumiant in hospitalized patients

Eli Lilly and Company got a second emergency use authorization for a COVID-19 therapy on 19 November, this time for its rheumatoid arthritis drug Olumiant (baricitinib) as part of combination therapy with Gilead Sciences, Inc.’s Veklury (remdesivir) in hospitalized patients who require supplemental oxygen. Previously, its experimental neutralizing antibody bamlanivimab got EUA approval from the US Food and Drug Administration earlier this month to treat patients with mild-to-moderate COVID-19 symptoms.

Based on data from the National Institute for Allergy and Infectious Diseases ACTT-2 trial, the EUA covers treatment of patients...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip